Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open‐label, crossover study

To determine if baseline characteristics, treatment efficacy, psychosocial outcomes or tolerability were associated with patient preference for sildenafil citrate (sildenafil) or tadalafil for treating erectile dysfunction (ED) in men naive to phosphodiesterase 5 inhibitor therapy.

[1]  B. Meibohm,et al.  The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy , 2007, International Journal of Impotence Research.

[2]  G. Hackett,et al.  Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. , 2006, The journal of sexual medicine.

[3]  S. Kimmel,et al.  ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Can Atorvastatin Improve the Response to Sildenafil in Men with Erectile Dysfunction Not Initially Responsive to Sildenafil? Hypothesis and Pilot Trial Results , 2006 .

[4]  G. Jackson,et al.  Erectile dysfunction and statin treatment in high cardiovascular risk patients , 2006, International journal of clinical practice.

[5]  F. Montorsi,et al.  An open‐label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy , 2005, BJU international.

[6]  R. Rosen,et al.  The Psychological and Interpersonal Relationship Scales: Assessing Psychological and Relationship Outcomes Associated with Erectile Dysfunction and Its Treatment , 2004, Archives of sexual behavior.

[7]  I. Goldstein,et al.  The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial , 2001, International Journal of Impotence Research.

[8]  H. Padma-nathan,et al.  On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction , 2001, International Journal of Impotence Research.

[9]  I. Goldstein,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.

[10]  I. Osterloh,et al.  Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. , 1999, Urology.

[11]  T F Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.

[12]  I. Osterloh,et al.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. , 1997, Urology.